ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Transgene (TNG.PA)
Transgene stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · Euronext Paris · France
€0.680▲ 0.00%
Prices as of Oct 27, 2026 · EUR
Chance of rising in 1 month
49%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Transgene in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Transgene
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Transgene a 49% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between €0.623 and €0.736; in 9 out of 10, between €0.538 and €0.853. Estimated annual volatility is 47%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- €193M
- Market cap (USD)
- $215M
- 52-week high
- €1.50
- 52-week low
- €0.670
- Revenue (12 months)
- €5.6M
- Net margin
- 0.0%
- Beta
- 0.72
What this means
ATLAS does not publish a fair value for TNG.PA right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks TNG.PA has traded between €0.670 and €1.50. Today it is 54.7% below that high and 1% above its low.
Its beta is 0.72: it tends to move less than the market.
About the company
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.
Want to see everything about Transgene?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Transgene do?
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.
What is the chance TNG.PA goes up next month?
49%: close to a coin flip. In half of the simulated outcomes, TNG.PA ends the month between €0.623 and €0.736.
How big is Transgene and what is its P/E ratio?
Transgene's market capitalization is €193M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is TNG.PA?
ATLAS estimates annual volatility at 47%. In a typical month, half of the outcomes end between €0.623 and €0.736.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer